drug
Undisclosed
Preclinicalupdated 6mo agoby $FATE FATE THERAPEUTICS INC
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 8all catalysts(0)
nothing on the calendar yet
Trials studying Undisclosed
News(10)
- Cellectis may cut 70% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 7h ago
- PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMOLess than two years after acquiring the assets, Lantheus is selling its CDMO unit and a New Jersey production plant to PharmaLogic.biospace · 2d ago
- Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera assetWith 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.biospace · 3d ago
- Coherus cuts 30% of staffers, Gyre makes post-acquisition layoffsCoherus is narrowing its pipeline projects while Gyre reorganizes after an acquisition, with both biotechs conducting workforce reductions.biospace · 5d ago
- Update: Compass submits psilocybin depression drug for approval after stock wobblesCompass Pathways has completed an FDA filing for COMP360, with an expected launch in the first half of next year. The update follows a reported regulatory submission for Usona Institute’s own psilo…biospace · 6d ago
- Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1BUnnatural Products has risen from founder Joshua Schwochert’s garage to an acquisition deal, valued at up to $1.15 billion, to join argenx.biospace · 6d ago
- Spruce spins out preclinical endocrinology program into newly formed AdrenyxSpruce Biosciences is spinning out a preclinical endocrinology program into a newly formed subsidiary called Adrenyx Biosciences, supported with up to $50 million from an unnamed investor.fiercebiotech · 7d ago
- Cash-strapped Vivoryon regains China rights to kidney disease prospect from SimcereVivoryon Therapeutics has regained the China rights to its kidney disease prospect as the German biotech’s cash reserves begin to dry up.fiercebiotech · 11d ago
- Boehringer bets big on China, offering $7B biobucks for Sino cancer programsBoehringer Ingelheim is building up its China strategy, inking a deal to develop new cancer treatments with Sino Biopharmaceutical just weeks after opening an R&D facility in Shanghai.biospace · 11d ago
- Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather…biospace · 11d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that